Eris Lifesciences Limited has informed the Exchange about Investor Presentation
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eris Lifesciences reported Q4 FY25 consolidated revenue of Rs. 705 crore, up 28% year-on-year, with EBITDA of Rs. 252 crore growing 70% and a margin of 35.8%. Full-year FY25 revenue rose 44% to Rs. 2,894 crore and EBITDA grew 51% to Rs. 1,017 crore, though net profit dipped 5.7% to Rs. 375 crore due to higher amortisation and finance costs from recent acquisitions. The company met 97% of its revenue guidance and 98% of EBITDA guidance. Domestic Branded Formulations delivered 10% organic growth in Q4, with the Biocon business growing 11% organically in its first year. For FY26, management guided consolidated revenue of Rs. 3,325–3,500 crore (15-21% growth), EBITDA margin of 36%, and consolidated EPS growth of 50%. The company also outlined a clear debt reduction path from 3.9x EBITDA in FY24 to 1.5x by FY26-end, and aims for a #3 rank in the anti-diabetes market by FY28.
The strong margin expansion, ahead-of-guidance debt reduction, and confident FY26 outlook (50% EPS growth) are positive for shareholders. The dip in FY25 net profit reflects acquisition integration costs rather than core business weakness, and the multi-year growth pipeline in Insulins, GLP-1, and Diabesity segments supports a constructive long-term outlook.